Pyrotinib
Soft Tissue Sarcoma
Gustave Roussy, Cancer Campus, Grand ParisSmall moleculePhase 3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 81/ 100
Competitive context
44 Active assets in the Soft Tissue Sarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Inno-206 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 | BB |
Cyclophosphamide Medigene AG | Phase 2 | BB |
Tislelizumab Gustave Roussy, Cancer Campus, Grand Paris | Phase 3 | BB |
Durvalumab Institut Bergonié | Phase 2 | B |
ETOPOSIDE Masonic Cancer Center, University of Minnesota | Phase 2 | B |
View all 50 →
Same molecule, other indications
Pyrotinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →